Summary
Biotechnology in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Synopsis
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United States
- Leading company profiles reveal details of key biotechnology market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States biotechnology market with five year forecasts
Reasons To Buy
- What was the size of the United States biotechnology market by value in 2016?
- What will be the size of the United States biotechnology market in 2021?
- What factors are affecting the strength of competition in the United States biotechnology market?
- How has the market performed over the last five years?
- What are the main segments that make up the United States's biotechnology market?
Key Highlights
The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.
The US biotechnology market is expected to generate total revenues of $164.6bn in 2016, representing a compound annual growth rate (CAGR) of 12.9% between 2012 and 2016.
The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $96.9bn, equivalent to 58.9% of the market's overall value.
The United States has been able to lure promising start-ups from UK and other countries via a better investment culture. However, China is putting the US under pressure in regards to investment and is making gains in regards to new breakthrough drugs.
'
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Amgen, Inc.
Baxter International Inc.
Biogen, Inc.
Merck and Co., Inc.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
Table 1: United States biotechnology industry value: $ billion, 2012-16(e)
Table 2: United States biotechnology industry category segmentation: $ billion, 2016(e)
Table 3: United States biotechnology industry geography segmentation: $ billion, 2016(e)
Table 4: United States biotechnology industry value forecast: $ billion, 2016-21
Table 5: Amgen, Inc.: key facts
Table 6: Amgen, Inc.: key financials ($)
Table 7: Amgen, Inc.: key financial ratios
Table 8: Baxter International Inc.: key facts
Table 9: Baxter International Inc.: key financials ($)
Table 10: Baxter International Inc.: key financial ratios
Table 11: Biogen, Inc.: key facts
Table 12: Biogen, Inc.: key financials ($)
Table 13: Biogen, Inc.: key financial ratios
Table 14: Merck and Co., Inc.: key facts
Table 15: Merck and Co., Inc.: key financials ($)
Table 16: Merck and Co., Inc.: key financial ratios
Table 17: United States size of population (million), 2012-16
Table 18: United States gdp (constant 2005 prices, $ billion), 2012-16
Table 19: United States gdp (current prices, $ billion), 2012-16
Table 20: United States inflation, 2012-16
Table 21: United States consumer price index (absolute), 2012-16
Table 22: United States exchange rate, 2012-15
Amgen, Inc.
Baxter International Inc.
Biogen, Inc.
Merck and Co., Inc.
